NCT06055959View on ClinicalTrials.gov

A Study to Evaluate Subcutaneous Zilucoplan in Pediatric Participants With Generalized Myasthenia Gravis

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

October 16, 2024

Primary Completion Date

November 16, 2026

Study Completion Date

December 25, 2026

Conditions
Generalized Myasthenia Gravis
Interventions
DRUG

Zilucoplan

Zilucoplan will be administered subcutaneously to pediatric study participants.

Trial Locations (9)

60611

RECRUITING

Mg0014 50168, Chicago

76208

RECRUITING

Mg0014 50574, Denton

Unknown

RECRUITING

Mg0014 40144, Milan

RECRUITING

Mg0014 40774, Katowice

RECRUITING

Mg0014 40218, Warsaw

RECRUITING

Mg0014 20104, Seoul

RECRUITING

Mg0014 20220, Seoul

RECRUITING

Mg0014 40735, Glasgow

RECRUITING

Mg0014 40736, London

All Listed Sponsors
lead

UCB Biopharma SRL

INDUSTRY